To the Editor In a small pilot study, Dr Osinusi and colleagues1 reported the safety and high sustained virologic response rate for combined treatment using ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, with sofosbuvir, an HCV NS5B polymerase inhibitor, in previously untreated, noncirrhotic patients with HCV genotype 1 and human immunodeficiency virus (HIV) co-infection. This study analyzed the changes in HIV parameters, such as HIV RNA level or CD4 T-lymphocyte count, and in renal function, such as serum creatinine level or estimated glomerular filtration rate.
Nozaki Y, Yanase M, Masaki N. Drug-Drug Interactions in Patients Co-infected With HCV and HIV. JAMA. 2015;314(2):186. doi:10.1001/jama.2015.6618